Swedish Multiple Sclerosis Blog
There is increasing evidence that impairment of the sensory system in multiple sclerosis contributes to balance and gait disorders. The majority of the disruption of sensation comes from spinal cord lesions. MS spinal lesions have a propensity to affect the posterior portion of the spinal cord. This involves the Posterior column-medial lemniscus pathway (PCML) (also known as the dorsal column-medial lemniscus pathway) that conveys localized sensations of fine touch, vibration, two-point discrimination, and proprioception (position sense) from the skin and joints. It transmits information from the body to the postcentral gyrus of the cerebral cortex (brain).
A recent research article, “Sensory integration balance training in patients with multiple sclerosis: A randomized, controlled trial”, highlights that rehabilitation targeted to this issue may help:
The Swedish MS Center, Neuro-ophthalmic Consultants Northwest, and Seattle Radiologists have formed a team for Walk MS to experience a great event and help the National MS Society fund research, advocate for change, and help people with MS live their best lives.
Walk MS is a day that ...
Experts from the Multiple Sclerosis Center at Swedish Neuroscience Institute and the National Multiple Sclerosis Society are bringing Multiple Sclerosis (MS) education and information to Tacoma. Come learn from a nationally recognized team of MS health care professionals, share your experience, and connect with others in the community living with MS.
When: Saturday, March 28
Time: 9:30 a.m. – 1:45 p.m.
Where: LeMay America's Car Museum, 2702 East D Street, Tacoma 98421
Cat: Kelly Bear
Breed: Domestic Longhair Calico
From: Eva's Eden - Cat Rescue, Blaine, Washington
Favorite toy: Toy bird that chirps
Favorite snack: Greenies treats
Unique fact: Only female cats can be Calico
Best trick: To walk on a leash or ride in a car
Describe your pet in one word: Love
How has your pet taught you to live life?
"She has shown unconditional love and taught me to ...
This recent study looked at 10 years of data on over 3,000 RRMS patients and found that Copaxone and IFN-β were similarly successful in reducing relapses. In the new study, researchers collected data on 3,326 RRMS patients who were using either IFN-β or Copaxone as their first-ever disease-modifying therapy (DMT) for at least 6 months, and had started treatment within 10 years of their first symptom. To be included in the study, patients also had to have had at least one relapse recorded during the two years leading up to the start of their initial DMT.
The researchers looked at ...
Bud Feuerstein is flying down the mountainside on an adaptive mono ski, a product of Outdoors For All (a nonprofit organization that enables recreational activities for individuals with disabilities).
Eight years prior, Bud would have been carving the slopes on his own set of skis, but due to a rare disease, he was left paralyzed from the chest down. Bud will never forget the night he was lying in bed and an odd sensation came over his body. Within seconds, he was paralyzed. Months later, he was diagnosed with transverse myelitis, a disease in the multiple sclerosis family. Having a better chance of winning the lottery, Bud was blindsided by this diagnosis, and his life was forever changed.
With this earth-shattering news, Bud had two fears: